The study concluded that the adjuvant group had a significant 74% decreased risk of biochemical prostate cancer recurrence compared to men who had only surgery.
When to Start ADT With A PSA Only Recurrence
Time to PSA Recurrence Is A Surrogate Endpoint for Prostate Cancer Survival
In an analysis of the NRG Oncology clinical trial NRG-RTOG 9202 it was shown that the interval of time to biochemical reoccurrence (PSA only or BCR), or the time it takes for previously treated prostate cancer to return as indicated by a prostate-specific antigen (PSA) rise, could be used as a surrogate endpoint for survival for men with locally advanced prostate cancer.